Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, Charles A. Veltri, Stephanie T. Weiss, Charles M. White & Oliver Grundmann. (2024) An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. Expert Review of Clinical Pharmacology 17:2, pages 131-142.
Read now
Read now
Micah Moore. (2023) Assessment of efficacy of drug evaluation and classification program in Florida. Traffic Injury Prevention 24:7, pages 552-558.
Read now
Read now
Alexandra Arenson, Cynthia I. Campbell & Ilan Remler. (2023) Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder – a narrative review. Journal of Addictive Diseases 0:0, pages 1-11.
Read now
Read now
Kirsten E. Smith, Kelly E. Dunn, David H. Epstein, Jeffrey D. Feldman, Albert Garcia-Romeu, Oliver Grundmann, Jack E. Henningfield, Christopher R. McCurdy, Jeffrey M. Rogers, Destiny Schriefer, Darshan Singh & Stephanie T. Weiss. (2022) Need for clarity and context in case reports on kratom use, assessment, and intervention. Substance Abuse 43:1, pages 1221-1224.
Read now
Read now
Viktoriya R. Broyan, Jessica K. Brar, Tristen Allgaier, Student & Jeffrey T. Allgaier. (2022) Long-term buprenorphine treatment for kratom use disorder: A case series. Substance Abuse 43:1, pages 763-766.
Read now
Read now
Cornel Stanciu, Saeed Ahmed, Samantha Gnanasegaram, Stephen Gibson, Thomas Penders, Oliver Grundmann & Christopher McCurdy. (2022) Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. The American Journal of Drug and Alcohol Abuse 48:5, pages 509-528.
Read now
Read now
Articles from other publishers (17)
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Gianluca Esposito, Johannes Gerardus Ramaekers, Massimo Pasquini & Ornella Corazza. (2023) Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review. Current Addiction Reports 10:2, pages 317-334.
Crossref
Crossref
Husna Hassan, Nani Draman, Raihan Hassan, Norsiah Ali & Salziyan Badrin. (2023) The use of opioid in treating a patient with kratom use disorder: A case report. Electronic Journal of General Medicine 20:3, pages em482.
Crossref
Crossref
Kirsten Elin Smith, Jeffrey M. Rogers & Jeffrey D. Feldman. (2023) Kratom’s Emergence and Persistence Within the US Polydrug Epidemic. Current Addiction Reports 10:2, pages 262-271.
Crossref
Crossref
Kirsten E. Smith, Jeffrey D. Feldman, Destiny Schriefer, Stephanie T. Weiss, Oliver Grundmann, Kelly E. Dunn, Darshan Singh, Christopher R. McCurdy, Gisela Butera & David H. Epstein. (2023) Diagnostic Ambiguities and Underuse of Clinical Assessment Tools: A Systematic Review of Case Reports on Kratom Addiction and Physical Dependence. Current Addiction Reports 10:2, pages 282-292.
Crossref
Crossref
Sushobhan Mukhopadhyay, Sampa Gupta, Jenny L. Wilkerson, Abhisheak Sharma, Lance R. McMahon & Christopher R. McCurdy. (2023) Receptor Selectivity and Therapeutic Potential of Kratom in Substance Use Disorders. Current Addiction Reports 10:2, pages 304-316.
Crossref
Crossref
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, Albert Garcia-Romeu, Justin C. Strickland & David H. Epstein. (2022) Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults. Journal of Addiction Medicine 16:6, pages 666-670.
Crossref
Crossref
Florian Lautenschlager, Manfred Weiss, Sigrun Feuerer & Norbert Wodarz. (2021) Kratom – eine kurze Übersicht für die SchmerzmedizinKratom – a short review for pain medicine. Der Schmerz 36:2, pages 128-134.
Crossref
Crossref
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, Oliver Grundmann, Christopher R. McCurdy, Destiny Schriefer & David H. Epstein. (2022) Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. Frontiers in Pharmacology 13.
Crossref
Crossref
Catherine W Striley, Carolin C Hoeflich, Andrew T Viegas, Lindsey A Berkowitz, Emily G Matthews, Leyla P Akin, Chidinma Iheanyi-Okeahialam, Urmeen Mansoor & Christopher R McCurdy. (2022)
Health Effects Associated With Kratom (
Mitragyna speciosa
) and Polysubstance Use: A Narrative Review
. Substance Abuse: Research and Treatment 16, pages 117822182210958.
Crossref
Crossref
Takato Hiranita, Samuel Obeng, Abhisheak Sharma, Jenny L. Wilkerson, Christopher R. McCurdy & Lance R. McMahon. 2022. Behavioral Pharmacology of Drug Abuse: Current Status. Behavioral Pharmacology of Drug Abuse: Current Status
35
76
.
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Ornella Corazza, Giuseppe Bersani & Johannes Gerardus Ramaekers. (2021) A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Human Psychopharmacology: Clinical and Experimental 37:1.
Crossref
Crossref
. (2021) Anxiolytics/mitragyna speciosa/opioid analgesics. Reactions Weekly 1872:1, pages 62-62.
Crossref
Crossref
David Vearrier & Oliver Grundmann. (2021) Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids. The Journal of Clinical Pharmacology 61:S2.
Crossref
Crossref
Rahimah Hassan, Sasidharan Sreenivasan, Christian P. Müller & Zurina Hassan. (2021) Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats. Frontiers in Pharmacology 12.
Crossref
Crossref
Alessandro E. Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John M. Corkery & Georgios D. Kotzalidis. (2021) Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. Frontiers in Psychiatry 12.
Crossref
Crossref
Rosalind Gittins & Samantha Cole. (2021) Buprenorphine for the management of kratom dependency during covid-19: A case report. Drug Science, Policy and Law 7, pages 205032452110211.
Crossref
Crossref
Antonio Metastasio, Elisabeth Prevete, Darshan Singh, Oliver Grundmann, Walter C. Prozialeck, Charles Veltri, Giuseppe Bersani & Ornella Corazza. (2020) Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study. Frontiers in Psychiatry 11.
Crossref
Crossref